162 related articles for article (PubMed ID: 7240669)
1. A possible role of endogenous opioids in the control of prolactin and luteinizing-hormone secretion in the human.
Veldhuis JD; Worgul TJ; Monsaert R; Hammond JM
J Endocrinol Invest; 1981; 4(1):31-6. PubMed ID: 7240669
[TBL] [Abstract][Full Text] [Related]
2. Differences in the opioid control of luteinizing hormone secretion between pathological and iatrogenic hyperprolactinemic states.
Petraglia F; De Leo V; Nappi C; Facchinetti F; Montemagno U; Brambilla F; Genazzani AR
J Clin Endocrinol Metab; 1987 Mar; 64(3):508-12. PubMed ID: 2880862
[TBL] [Abstract][Full Text] [Related]
3. Evidence for an increased opioid inhibition of luteinizing hormone secretion in hyperprolactinemic patients with pituitary microadenoma.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 Mar; 50(3):427-30. PubMed ID: 7358828
[TBL] [Abstract][Full Text] [Related]
4. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma.
Seki K; Kato K; Shima K
J Clin Endocrinol Metab; 1986 Nov; 63(5):1225-8. PubMed ID: 3760121
[TBL] [Abstract][Full Text] [Related]
5. Effects of naloxone on prolactin-secreting pituitary adenomas.
Shima K; Chigasaki H; Seki K
Neurol Med Chir (Tokyo); 1990 Feb; 30(2):109-12. PubMed ID: 1695330
[TBL] [Abstract][Full Text] [Related]
6. The effect of nalmefene on pulsatile secretion of luteinizing hormone and prolactin in men.
Graves GR; Kennedy TG; Weick RF; Casper RF
Hum Reprod; 1993 Oct; 8(10):1598-603. PubMed ID: 8300813
[TBL] [Abstract][Full Text] [Related]
7. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH, follicle-stimulating hormone, prolactin, and beta-endorphin secretion.
Baranowska B; Rozbicka G; Jeske W; Abdel-Fattah MH
J Clin Endocrinol Metab; 1984 Sep; 59(3):412-6. PubMed ID: 6086696
[TBL] [Abstract][Full Text] [Related]
8. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
[TBL] [Abstract][Full Text] [Related]
9. Suppression of pulsatile LH secretion, pituitary GnRH receptor content and pituitary responsiveness to GnRH by hyperprolactinemia in the male rat.
Fox SR; Hoefer MT; Bartke A; Smith MS
Neuroendocrinology; 1987 Oct; 46(4):350-9. PubMed ID: 2823160
[TBL] [Abstract][Full Text] [Related]
10. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
Quigley ME; Sheehan KL; Casper RF; Yen SS
J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
[TBL] [Abstract][Full Text] [Related]
11. Responsiveness of gonadotropin secretion to infusion of an opiate-receptor antagonist in hypogonadotropic individuals.
Veldhuis JD; Kulin HE; Warner BA; Santner SJ
J Clin Endocrinol Metab; 1982 Oct; 55(4):649-53. PubMed ID: 6809778
[TBL] [Abstract][Full Text] [Related]
12. Endorphins and the regulations of the human menstrual cycle.
Blankstein J; Reyes FI; Winter JS; Faiman C
Clin Endocrinol (Oxf); 1981 Mar; 14(3):287-94. PubMed ID: 6790206
[TBL] [Abstract][Full Text] [Related]
13. Effects of hyperprolactinemia on the control of luteinizing hormone and follicle-stimulating hormone secretion in the male rat.
Smith MS; Bartke A
Biol Reprod; 1987 Feb; 36(1):138-47. PubMed ID: 3105612
[TBL] [Abstract][Full Text] [Related]
14. Naloxone-induced prolactin secretion in women: evidence against a direct prolactin stimulatory effect of endogenous opioids.
Cetel NS; Quigley ME; Yen SS
J Clin Endocrinol Metab; 1985 Jan; 60(1):191-6. PubMed ID: 3964791
[TBL] [Abstract][Full Text] [Related]
15. Role of endogenous opioid peptides in the initiation of the midcycle luteinizing hormone surge in normal cycling women.
Rossmanith WG; Mortola JF; Yen SS
J Clin Endocrinol Metab; 1988 Oct; 67(4):695-700. PubMed ID: 3138276
[TBL] [Abstract][Full Text] [Related]
16. Impairment of opioid control of luteinizing hormone secretion in menstrual disorders.
Petraglia F; D'Ambrogio G; Comitini G; Facchinetti F; Volpe A; Genazzani AR
Fertil Steril; 1985 Apr; 43(4):534-40. PubMed ID: 3886435
[TBL] [Abstract][Full Text] [Related]
17. Evidence for endogenous opioid modulation of serum luteinizing hormone and prolactin in the steer.
Peck DD; Thompson FN; Stuedemann JA; Leshin LS; Kiser TE
J Anim Sci; 1988 Dec; 66(12):3197-201. PubMed ID: 3230079
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin secretion in rats bearing a prolactin-secreting pituitary tumor: effects of naloxone administration.
Lamberts SW; Zuiderwijk JM; Bons EG; Uitterlinden P; de Jong FH
Fertil Steril; 1981 May; 35(5):557-62. PubMed ID: 6785115
[TBL] [Abstract][Full Text] [Related]
19. Naloxone increases the frequency of pulsatile luteinizing hormone secretion in women with hyperprolactinemia.
Cook CB; Nippoldt TB; Kletter GB; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Nov; 73(5):1099-105. PubMed ID: 1939525
[TBL] [Abstract][Full Text] [Related]
20. Hypogonadism, galactorrhoea and hyper-prolactinaemia: Evaluation of pituitary gonadotrophins reserve before and under bromocriptine.
Asfour M; L'Hermite M; Hedouin-Quincampoix M; Fossati P
Acta Endocrinol (Copenh); 1977 Apr; 84(4):738-49. PubMed ID: 322432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
